Zhang Tian, Li Hao, Zhang Yang, Wang Pei, Bian Huijie, Chen Zhi-Nan
Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Department of Laboratory Medicine and Pathology, The People's Liberation Army 59 Central Hospital, Kaiyuan, Yunnan 661600, P.R. China.
Oncol Lett. 2018 Mar;15(3):3042-3048. doi: 10.3892/ol.2017.7701. Epub 2017 Dec 28.
Cluster of differentiation 147 (CD147), pituitary tumor transforming gene (PTTG) and CD44v6 are proteins involved in the epithelial-mesenchymal transition (EMT). To investigate the prognostic value of CD147 and PTTG, and CD44v6 expression in esophageal squamous cell carcinoma (ESCC), tissue microarray specimens from 76 patients with ESCC were evaluated by immunohistochemistry staining and scored by intensity and proportion of positive areas. Expression levels of CD147, PTTG and CD44v6 were higher in tumor tissues than in matched adjacent tissues. CD147 expression was positively associated with lymph node metastasis (P=0.025) and American Joint Committee on Cancer (AJCC) system clinical grades (P=0.037). CD147 expression was positively correlated with the expression levels of PTTG (R=0.369; P=0.001) and CD44v6 (R=0.320; P=0.005). In addition, Kaplan-Meier analysis indicated that positive expression of CD147, PTTG and CD44v6 was significantly associated with poor overall survival times (P=0.045, P=0.014 and P=0.027, respectively). Patients exhibiting CD147-PTTG co-expression, CD147-CD44v6 co-expression and CD147-PTTG-CD44v6 triple-positive expression had the poorest overall survival rates. In conclusion, the expression of EMT-associated proteins, including CD147, PTTG and CD44v6, was significantly associated with poor survival in ESCC and these novel targets may serve as potential biomarkers for anticancer therapies.
分化簇147（CD147）、垂体肿瘤转化基因（PTTG）和CD44v6是参与上皮-间质转化（EMT）的蛋白质。为了研究CD147、PTTG和CD44v6表达在食管鳞状细胞癌（ESCC）中的预后价值，对76例ESCC患者的组织芯片标本进行免疫组化染色评估，并根据阳性区域的强度和比例进行评分。肿瘤组织中CD147、PTTG和CD44v6的表达水平高于配对的癌旁组织。CD147表达与淋巴结转移（P = 0.025）及美国癌症联合委员会（AJCC）系统临床分级（P = 0.037）呈正相关。CD147表达与PTTG表达水平（R = 0.369；P = 0.001）及CD44v6表达水平（R = 0.320；P = 0.005）呈正相关。此外，Kaplan-Meier分析表明，CD147、PTTG和CD44v6的阳性表达与总体生存时间短显著相关（分别为P = 0.045、P = 0.014和P = 0.027）。表现出CD147-PTTG共表达、CD147-CD44v6共表达及CD147-PTTG-CD44v6三阳性表达的患者总体生存率最差。总之，包括CD147、PTTG和CD44v6在内的EMT相关蛋白的表达与ESCC患者的不良生存显著相关，这些新靶点可能作为抗癌治疗的潜在生物标志物。
